0 Read eBook for: drug pricing [PDF]

The Price Of Global Health

The Price of Global Health PDF

Get This Book

Author: Ed Schoonveld
Publisher: Routledge
ISBN: 131701930X
Size: 78.87 MB
Format: PDF, ePub
Category : Business & Economics
Languages : en
Pages : 494
View: 2373


Public debate on the rising cost of new biotechnology drug treatments has intensified over the last few years as healthcare budget pressures have mounted under a strained economy. Meanwhile, the demand for new, effective medical and drug treatments continues to rise as unhealthy lifestyles cause further increases in diabetes and cardiovascular disease. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences, from healthcare industry professionals to policy makers and the broader public, to gain a better understanding of this highly complex and emotionally charged field. The Price of Global Health is recognized as a valued and unique reference book that covers a complete array of topics related to global pharmaceutical pricing. It contains an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by, the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs. The second edition includes new chapters on payer value story development, oncology, orphan drugs and payer negotiations. Furthermore, many country chapters have been substantially updated to reflect changes in the healthcare systems, including the Affordable Care Act in the US, AMNOG in Germany, medico-economic requirements in France and many other country-specific changes. Lastly, almost every chapter has been updated with new examples and illustrations.

Pharmaceutical Prices In The 21st Century

Pharmaceutical Prices in the 21st Century PDF

Get This Book

Author: Zaheer-Ud-Din Babar
Publisher: Springer
ISBN: 3319121693
Size: 73.70 MB
Format: PDF, ePub, Mobi
Category : Business & Economics
Languages : en
Pages : 411
View: 1060


This book provides an overview of the global pharmaceutical pricing policies. Medicines use is increasing globally with the increase in resistant microbes, emergence of new treatments, and because of awareness among consumers. This has resulted in increased drug expenditures globally. As the pharmaceutical market is expanding, a variety of pharmaceutical pricing strategies and policies have been employed by drug companies, state organizations and pharmaceutical pricing authorities.

Drug Pricing And Pharmaceutical Patenting Practices

Drug Pricing and Pharmaceutical Patenting Practices PDF

Get This Book

Author: Kevin J Hickey
Publisher:
ISBN:
Size: 19.83 MB
Format: PDF
Category :
Languages : en
Pages : 50
View: 868


Intellectual property (IP) rights in pharmaceuticals are typically justified as necessary to allow manufacturers to recoup their substantial investments in research, development, and regulatory approval. IP law provides exclusive rights in a particular invention or product for a certain time period, potentially enabling the rights holder (e.g., a brand-name drug manufacturer) to charge higher-than-competitive prices. If rights holders are able to charge such prices, they have an incentive to lengthen the period of exclusive rights as much as possible. Indeed, some commentators allege that pharmaceutical manufacturers have engaged in patenting practices that unduly extend the period of exclusivity. These critics argue that these patenting practices are used to keep drug prices high, without any benefit for consumers or innovation. Criticisms center on four such practices: * "Evergreening": So-called patent "evergreening" is the practice of filing for new patents on secondary features of a particular product as earlier patents expire, thereby extending patent exclusivity past the original twenty-year term. Later-filed patents may delay or prevent entry by competitors, thereby allowing the brand-name drug manufacturer (the brand) to continue charging high prices. * "Product Hopping": Generic drug manufacturers allege that as patents on a particular product expire, brand manufacturers may attempt to introduce and switch the market to a new, similar product covered by a later-expiring patent-a process known as "product hopping" or "product switching." This practice takes two forms: a "hard switch," where the older product is removed from the market, and a "soft switch," where the older product is kept on the market with the new product. In either case, the brand will focus its marketing on the new product in order to limit the market for any generic versions of the old product. * "Patent Thickets": Generic and biosimilar companies also allege that the brands create "patent thickets" by filing numerous patents on the same product. These thickets allegedly prevent generics from entering the market due to the risk of infringement and the high cost of patent litigation. * "Pay-for-Delay" Settlements: Litigation often results when a generic or biosimilar manufacturer attempts to enter the market with a less expensive version of a branded pharmaceutical. Core issues usually include whether the brand's patents are valid, and whether the generic or biosimilar product infringes those patents. Rather than litigate these issues to judgment, however, the parties will often settle. Such settlements may involve the brand paying the generic or biosimilar to stay out of the market-referred to as "reverse payment" or "pay-for-delay" settlements. These settlements are allegedly anticompetitive because they allow the brand to continue to charge high prices without risking invalidation of its patent, thus unjustifiably benefiting the settling companies at the expense of the consumer. Drug manufacturers respond that their patenting practices protect new, innovative inventions, as Congress intended when it created the patent system. In their view, the terms for these practices are unfairly pejorative, or, at most, describe outlier behavior by a few companies. Defenders of these patenting practices reject their characterization as anticompetitive and emphasize that strong patent rights are needed to encourage innovation and life-saving research and development efforts. In recent years, some commentators and Members of Congress have proposed patent reforms that seek to limit or curtail these patenting practices, which some perceive as contributing to high prices for pharmaceutical products.

Drug Pricing Analysis

Drug Pricing Analysis PDF

Get This Book

Author: United States. Congress. House. Committee on Government Reform
Publisher:
ISBN:
Size: 43.78 MB
Format: PDF, ePub
Category : Drugs
Languages : en
Pages : 3
View: 4961



Brand New Prescription Drug Pricing

Brand New Prescription Drug Pricing PDF

Get This Book

Author: John E. Dicken
Publisher: DIANE Publishing
ISBN: 1437927017
Size: 63.41 MB
Format: PDF
Category :
Languages : en
Pages : 40
View: 2690


The growing cost of brand-name prescription drugs (BNPD) -- FDA-approved drug products that typically have patent protection -- is a concern for patients, payers, and providers of health care -- particularly when price increases are large and occur suddenly. A 2008 congressional hearing drew attention to some small market prescription drugs that had an extraordinary price increase -- 100% or more at a single point in time. This report examined extraordinary price increases for BNPD. It examined the: (1) frequency of extraordinary price increases for BNPD from 2000 to 2008; (2) characteristics of the BNPD that had extraordinary price increases; and (3) factors that contributed to the extraordinary price increases experienced by these BNPD. Illustrations.

Prescription Drug Pricing In Independent And Chain Drugstores

Prescription Drug Pricing in Independent and Chain Drugstores PDF

Get This Book

Author: Herbert R. Northrup
Publisher: University of Pennsylvania Press
ISBN: 1512818305
Size: 74.71 MB
Format: PDF, Docs
Category : Business & Economics
Languages : en
Pages : 216
View: 4740



The Right Price

The Right Price PDF

Get This Book

Author: Peter J. Neumann
Publisher: Oxford University Press
ISBN: 0197512909
Size: 21.96 MB
Format: PDF, ePub, Mobi
Category : Medical
Languages : en
Pages : 312
View: 2056


The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value.

Prescription Drugs Oversight Of Drug Pricing In Federal Programs

Prescription Drugs  Oversight of Drug Pricing in Federal Programs PDF

Get This Book

Author:
Publisher: DIANE Publishing
ISBN: 9781422313558
Size: 72.79 MB
Format: PDF, ePub
Category :
Languages : en
Pages :
View: 6074



Drugs Money And Secret Handshakes

Drugs  Money  and Secret Handshakes PDF

Get This Book

Author: Robin Feldman
Publisher: Cambridge University Press
ISBN: 1108659500
Size: 42.88 MB
Format: PDF
Category : Law
Languages : en
Pages :
View: 286


In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.

Setting The Price Of Health

Setting the Price of Health PDF

Get This Book

Author: Jennie Litvack
Publisher:
ISBN:
Size: 79.40 MB
Format: PDF, ePub, Docs
Category : Drugs
Languages : en
Pages : 31
View: 6253



Prescription Drug Pricing Background Discount Programs And Cost Lowering Strategies

Prescription Drug Pricing  Background  Discount Programs and Cost Lowering Strategies PDF

Get This Book

Author: Elias B. Toft
Publisher: Nova Snova
ISBN: 9781536176681
Size: 16.61 MB
Format: PDF, ePub, Docs
Category :
Languages : en
Pages : 248
View: 6238


Chapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entitiesâeligible clinics, hospitals, and othersâin order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18â64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugsâcopies of brand-name drugsâlead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate.

Prescription Drug Pricing

Prescription Drug Pricing PDF

Get This Book

Author: Jonathan R. Dickson
Publisher: Nova Science Pub Incorporated
ISBN: 9781613246399
Size: 13.73 MB
Format: PDF, ePub
Category : Political Science
Languages : en
Pages : 139
View: 7721


The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.

Examining Two Approaches To U S Drug Pricing

Examining Two Approaches to U S  Drug Pricing PDF

Get This Book

Author:
Publisher:
ISBN:
Size: 62.95 MB
Format: PDF, Docs
Category : Drugs
Languages : en
Pages : 34
View: 7687


While policymakers value the need to support continued innovation, they also seek ways to increase the affordability and accessibility of drugs. To date, many of the options to mitigate the high price of drugs have focused on increasing competition and transparency in the pharmaceutical sector as well as increasing value-based payments based on outcomes achieved. However, this report examines two additional tools: external reference pricing and internal reference pricing. The varied use of external and internal reference pricing schemes in developed, market-oriented countries such as Germany, Switzerland, and Denmark, all of which have a relatively short time-to-market for pharmaceutical drugs, demonstrates that these tools could be effective in the United States to mitigate high drug prices.

Prescription Drug Pricing

Prescription Drug Pricing PDF

Get This Book

Author: Sarah F. Jaggar
Publisher:
ISBN:
Size: 46.25 MB
Format: PDF, Mobi
Category : Drugs
Languages : en
Pages : 8
View: 1272



Big Pharma And Drug Pricing

Big Pharma and Drug Pricing PDF

Get This Book

Author: Pete Schauer
Publisher:
ISBN: 9781534501829
Size: 38.72 MB
Format: PDF
Category : Drugs
Languages : en
Pages : 224
View: 6384


Americans pay among the highest prices for prescription drugs, thanks to government legislation and the powerful pharmaceutical lobbies. The effect has been disastrous, with many citizens obtaining cheaper medicine from Canada, and others forgoing it altogether at the risk of their health. These crippling prices are set by "big pharma," at the insistence of those who support free trade. Consumers call the pharmaceutical companies greedy and selfish, but these companies also enact change, through scientific research, curing of diseases, and community outreach. What is the answer to this complex issue? Readers will learn about the conflicts and potential solutions in this compelling volume.

Back to Top